Carl Zeiss Meditec AG Deep Dive China | Market Leadership & Long-Term Growth Strategy

Carl Zeiss Meditec AG Deep DiveCarl Zeiss Meditec: China Strategy Deep Dive and Growth OutlookPresented by Sebastian Frericks, Head of Group Finance & Investor RelationsIn this comprehensive China-focused investor presentation, Sebastian Frericks, Head of Group Finance & Investor Relations at Carl Zeiss Meditec, provides a strategic deep dive into the company’s operations and growth opportunities in one of the world’s most dynamic and promising healthcare markets.🇨🇳 China – A Strategic Growth EngineChina is Carl Zeiss Meditec’s largest single-country market, now contributing approximately 26% of group revenue — up from just 6% a decade ago. This growth has been driven by:- Rapid urbanization- Rising middle-income population- High myopia prevalence- Aging demographics fueling demand for cataract and retinal solutionsDespite short-term challenges such as anti-corruption reforms, post-COVID consumer sentiment softness, and volume-based procurement (VBP) schemes, Carl Zeiss Meditec has remained resilient. The long-term fundamentals in China remain intact and highly attractive.🔍 Segment Highlights👁 Refractive SurgeryZEISS is the undisputed market leader in China with an estimated >50% market shareOver 1,200 installed VISUMAX femtosecond lasers, with more than 15% due for replacementNew platforms VISUMAX® 800 and PRESBYOND® launched for high-growth refractive and presbyopia treatmentsSMILE procedure accounts for 70% of volume, significantly ahead of LASIK (30%)Despite macro headwinds, market share continues to grow👁 Intraocular Lenses (IOL) & Cataract SurgeryFastest-growing surgical segment for ZEISS in ChinaIOL volumes growing ~20% CAGR in FY23/24, driven by VBP pricing reset and increased accessStrong performance in premium IOLs (multifocal & presbyopia-correcting), with ~30% growthSignificant runway to close the cataract surgery volume gap with the US🧬 Retina & Surgical SolutionsZEISS among the top 3 global players in posterior segment surgeryIntegration of DORC expanding ZEISS’ retinal surgery workflowNew product approvals in FY24 enabling rollout in China🏭 ZEISS Local Presence in ChinaZEISS is deeply embedded in the Chinese healthcare ecosystem through:Manufacturing facilities in Suzhou and GuangzhouChina-specific R&D capabilities and product designExperienced local regulatory and clinical affairs teamsExtensive sales and service infrastructure across the countryRemarkably, ZEISS brand awareness in China exceeds that of its home market, Germany — a legacy of decades of optical innovation in telescopes, eyewear, and imaging systems.📉 Addressing Short-Term HeadwindsVBP tenders have reduced prices (~40%) but expanded patient accessPost-COVID overstocking in refractive consumables has normalized“Buy local” policies are offset by ZEISS’ Chinese manufacturing footprint📈 Long-Term Strategy & Growth LeversPromote full refractive portfolio, especially VISUMAX® 800 and PRESBYOND®Accelerate premium IOL penetration and clear lens exchange programsExpand DORC-based retinal surgery platformDeepen localization to navigate regulatory and cost environmentsCapitalize on brand strength, IP leadership, and ongoing innovation to stay ahead of domestic competitors▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ T&C This publication is intended solely for informational purposes and does not constitute investment advice. By using this website, you agree to our terms and conditions as outlined on www.seat11a.com/legal and www.seat11a.com/imprint.